08:00 , Dec 11, 2006 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 12/8 cls Acambis (LSE:ACM; ACAM) Bridgewell Shawn Manning New Buy 3% 104p Manning set a 146p target. He expects approval...
07:00 , Oct 2, 2006 |  BioCentury  |  Finance

Ebb & Flow

ImClone (IMCL) investors shaved $1.30 off the stock last week as they digested news that FDA approved a competing colorectal cancer antibody - Vectibix panitumumab - from Amgen (AMGN). The main question now is whether...
00:32 , May 5, 2006 |  BC Extra  |  Financial News

Allergy raises $33.6 million

Allergy Therapeutics (LSE:AGY) raised L19 million ($33.6 million) through a placing of 19 million shares at 100p. Bridgewell was the advisor. AGY sells its Pollinex Quattro allergy vaccines in Europe on a named-patient basis. Its...
00:24 , Apr 11, 2006 |  BC Extra  |  Financial News

Allergy Therapeutics proposes offering

Allergy Therapeutics (LSE:AGY) plans to raise L19 million ($33.1 million) through a placing of 19 million shares at 100p, which is a 7% discount to AGY's close of 108p on Friday. The placing is contingent...
07:00 , May 24, 2004 |  BC Week In Review  |  Company News

Profile Therapeutics plc, Respironics deal

RESP said it will make a cash offer of 50.9p per share for respiratory company PTP, valuing the company at about £25.3 million ($44.6 million). The offer is a 27% premium on PTP's closing price...
07:00 , May 21, 2004 |  BC Extra  |  Company News

Respironics to acquire PTP

RESP said it will make a cash offer of 50.9p per share for respiratory company Profile Therapeutics (LSE:PTP), valuing the company at about L25.3 million ($44.6 million). The offer is a 27% premium to PTP's...